Trial reportAmerican journal of reproductive immunology (New York, N.Y. : 1989)2012
The mucin MUC16 (CA125) binds to NK cells and monocytes from peripheral blood of women with healthy pregnancy and preeclampsia.
Trial report in American journal of reproductive immunology (New York, N.Y. : 1989), 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- Risk-stratified CA125 screening integrating CA125 trajectories, trajectory-specific progression and transvaginal ultrasound for ovarian cancer.Journal of ovarian research · 2024Article
- The association among cancer-antigen-125 and pre-eclampsia and estimated fetal weight: A case-control study.International journal of reproductive biomedicine · 2024Article
- Sialic Acids on Tumor Cells Modulate IgA Therapy by Neutrophils via Inhibitory Receptors Siglec-7 and Siglec-9.Cancers · 2023Article
- Article
- The central role of natural killer cells in preeclampsia.Frontiers in immunology · 2023Review
- Cellular immune responses in the pathophysiology of preeclampsia.Journal of leukocyte biology · 2022Review
- Targeting Myeloid Checkpoint Molecules in Combination With Antibody Therapy: A Novel Anti-Cancer Strategy With IgA Antibodies?Frontiers in immunology · 2022Review
- Regulation of the innate immune cells during pregnancy: An immune checkpoint perspective.Journal of cellular and molecular medicine · 2021Review
- MUC16 promotes EOC proliferation by regulating GLUT1 expression.Journal of cellular and molecular medicine · 2021Article
- Knockdown of MUC16 (CA125) Enhances the Migration and Invasion of Hepatocellular Carcinoma Cells.Frontiers in oncology · 2021Article
- The Ovarian Cancer Tumor Immune Microenvironment (TIME) as Target for Therapy: A Focus on Innate Immunity Cells as Therapeutic Effectors.International journal of molecular sciences · 2020Review
- Nanotechnology and Immunotherapy in Ovarian Cancer: Tracing New Landscapes.The Journal of pharmacology and experimental therapeutics · 2019Review
- MUC16 as a novel target for cancer therapy.Expert opinion on therapeutic targets · 2018Review
- Diverse properties of the mesothelial cells in health and disease.Pleura and peritoneum · 2016Review
- Tumor necrosis factor-α and interferon-γ stimulate MUC16 (CA125) expression in breast, endometrial and ovarian cancers through NFκB.Oncotarget · 2016Article
- Endogenous airway mucins carry glycans that bind Siglec-F and induce eosinophil apoptosis.The Journal of allergy and clinical immunology · 2015Article
- Lectin galactoside-binding soluble 3 binding protein (LGALS3BP) is a tumor-associated immunomodulatory ligand for CD33-related Siglecs.The Journal of biological chemistry · 2014Article
- Aberrant glycosylation of plasma proteins in severe preeclampsia promotes monocyte adhesion.Reproductive sciences (Thousand Oaks, Calif.) · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
problemMUC16 (CA125) released from ovarian tumors binds to NK cells and monocytes via the inhibitory receptor Siglec-9. Here, we investigate whether MUC16 also binds to circulating immune cells during pregnancy and in women with preeclampsia. METHOD OF STUDY: MUC16 binding was monitored by flow cytometry and immunoprecipitation, and RT-PCR was used to monitor indigenous expression in immune cells. Serum CA125 levels were measured by a clinical assay.
resultsMUC16 was equally distributed on Siglec-9(pos) CD16(pos)/CD56(dim) and CD16(neg)/CD56(br) NK cells in the healthy pregnant and preeclampsia groups. While serum CA125 levels and number of NK and monocytes were similar, increased binding of MUC16 was observed on these immune cells in the preeclampsia cohort as compared to the healthy pregnant samples.
conclusionMUC16 binding to NK cells and monocytes likely contributes to tolerance of the fetal allograft from maternal responses and may also serve as a novel biomarker for preeclampsia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.